Acta Medica Okayama volume74 issue5
2020-10 発行
Hirabae, Atsuko
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ichihara, Eiki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Kaken ID
publons
Sunami, Ryota
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ota, Moeko
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Iwamoto, Yoshitaka
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Maeda, Yoshinobu
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
researchmap
We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.
lung cancer
immune checkpoint inhibitors
pembrolizumab
hyperprogression